Objective: This systematic literature review (SLR) evaluates the global burden of treatment-induced vasomotor symptoms (VMSs) in individuals with breast cancer receiving tamoxifen or aromatase inhibitors (AIs). This evidence concerns the gene CYP19A1 and breast carcinoma.